Robocath — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Robocath is a pioneering private company in the vascular robotics space, with its CE-marked R-One/R-One+ platform commercially available in Europe, Africa, and China. The company focuses on improving procedural precision and clinician safety from radiation during percutaneous coronary interventions (PCI). With over 70 employees and a foundation in unique bionic technology, Robocath aims to become a global leader in the digital evolution of interventional cardiology and vascular medicine.

Cardiovascular

Technology Platform

Open-architecture robotic platform (R-One/R-One+) for interventional vascular procedures. Features bionic technology for precise instrument control, a suite of navigation and locking features (R-GRASP, R-LOCK, EASY-LOOP), and remote operation for physician radioprotection (RADIO-STOP). Compatible with leading third-party devices and imaging systems.

Opportunities

The large and growing global incidence of coronary and vascular diseases drives continuous demand for improved interventional tools.

The push for greater procedural precision, reduced radiation exposure for staff, and the trend towards digitalization in healthcare create a strong tailwind for robotic adoption.

Expansion into high-growth markets like China presents a significant geographical opportunity.

Risk Factors

Faces intense competition from larger, well-capitalized medical technology corporations with established robotic platforms.

Market adoption is slowed by high capital costs, workflow integration challenges, and the need for robust health-economic data.

Regulatory hurdles for new market entries (e.g., FDA clearance) are significant and costly.

Competitive Landscape

Robocath competes in the vascular robotics segment against major players like Siemens Healthineers (Corindus pathway) and Philips, which offer integrated robotic systems for coronary and peripheral interventions. Its primary competitive differentiation is its open architecture, allowing compatibility with a wide range of existing devices, unlike some closed, proprietary systems. This strategy lowers adoption barriers for cost-conscious hospitals.

More companies in Digital Health & Biotech SaaS →More companies in France →